At SLEEP 2026, the head of orexin franchise development and neuroscience programs at Takeda discussed new phase 3 data for oveporexton in patients with narcolepsy type 1. [WATCH TIME: 5 minutes]
Elena Koundourakis, PhD
Advertisement
Head of Orexin Franchise Development and Neuroscience Programs at Takeda.
Articles by Elena Koundourakis, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
uniQure Submits BLA for Gene Therapy in HD, AAN, AHS Issue Updated Guideline on Migraine Prevention, CTE Prevalence, Brain Donation Findings in Former NFL Players
2
EU Approves Modified-Release Carbidopa/Levodopa Capsules for Parkinson Disease Motor Fluctuations
3
Phase 4 Study Highlights Valbenazine's Positive Impact on Patient-Reported Quality of Life, Daily Functioning in Tardive Dyskinesia
4
American Academy of Neurology, American Headache Society Issue Updated Guideline on Migraine Prevention
5